저용량 스트렙토조토신 유도 당뇨 흰쥐에서 화살나무·상엽 복합 처방의 항당뇨 활성

Antidiabetic Activity of Formula Containing Euonymus Alatus (Thunb.) Sieb. And Mori Folium in Multiple Low Dose Streptozotocin-induced Diabetic Rats

We investigated the hypoglycemic effect of formula containing Euonymus alatus (EA) and Mori Folium (MF) in multiple low dose (MLD) streptozotocin (STZ)-induced diabetic rats. In order to induce hyperglycemic state 25 mg/kg of STZ was injected intraperitoneally for 5 consecutive days. SD rats were randomly divided into diabetic control and treatment groups. Treatment groups were administered with either 250 mg/kg of EA and 250 mg/kg of MF (EIM1), or 500 mg/kg of EA mixed with same dose of MF (E2M2) for 3 weeks. Blood glucose levels and body weights were measured every 5th or 6th day. EIM1 and E2M2 both significantly reduced food intake, water intake, and fasting blood and urine glucose levels as compared to those in diabetic control group in a dose dependent manner, Body weight in diabetic control group was increased slightly after 3 weeks. Treatment group, however, showed gradual increase in body welghts during 3 week-period. While plasma insulin levels of the diabetic control group were decreased to the level of 387±14 pg/ml from 534±36 pg/ml, those levels in EIMI and E2M2-treated groups were both markedly increased by 13% and 26%, respectively, Urine glucose levels in EIM1 and E2M2-treated groups were also remarkably reduced by 17 and 26% compared to the levels of diabetic control group. While expression of membrane-bound glucose transporter-4 (GLUT-4) protein in skeletal muscle was reduced by 45% in diabetic control compared to the normal control, GLUT-4 protein expressions in EIM1 and E2M2-treated groups were augmented by 2 and 3.5 times compared to the diabetic control, respectively. Pancreatic HE staining experiments showed that E2M2-treated group revealed much less infiltrated mononuclear cells, indicating that E2M2 efficiently blocked insulitis induced by multiple low dose streptozotocin. Tlken together, we conclude that formula containing EA and MF may prevent or delay the development of hyperglycemia through overexpression of GLUT-4 protein in skeletal muscle and prevention of insulitis.